Table 1 Patient characteristics

Age

Median (IQR)

27.5 (23–30)

27 (23–31)

0.960

WHO Stage N. (%)

I

17 (63)

211 (75.9)

0.493

II

7 (25.9)

47 (16.9)

III

3 (11.1)

19 (6.8)

IV

1 (0.4)

Week of gestation at ART initiation

Median (IQR)

27 (24–31)

26 (24–30)

0.576

Duration of ART during pregnancy

Median days (IQR)

78 (49–92)

70 (44–95)

0.828

ART regimen, N. (%)

Stavudine/Lamivudine/Nevirapine

15 (53.6)

148 (52.7)

Zidovudine/Lamivudine/Nevirapine

13 (46.4)

133 (47.3)

0.927

Baseline Hemoglobin (g/dl)

Median (IQR)

9.8 (9.0-10.9)

10.3 (9.5-11.3)

0.082

Baseline Platelets (x10³/mm³)

Median (IQR)

177 (126–262)

202 (168–249)

0.106

Baseline ALT (IU/ml)

Median (IQR)

15.5 (12.2-27.1)

12.5 (10–17.8)

0.043

Baseline AST (IU/ml)

Median (IQR)

28 (23.3-37.1)

25.1 (19.3-34.2)

0.209

Baseline CD4+ cell count/mm³

Median (IQR)

327 (193–495)

340 (219–494)

0.666

Baseline HIV-RNA log₁₀/ml

Median (IQR)

3.89 (3.0-4.5)

4.09 (3.4-4.6)

0.297